STK19 inhibitors for treatment of cancer

1. A compound of Formula I:

wherein:

X is

Y is N(R 3 R 4 ), aryl,

R 3 and R 4 are independently hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of cycloalkyl, heterocyclyl, aryl and heteroaryl can be substituted or unsubstituted, and wherein the alkyl is methyl, ethyl, i-propyl, n-butyl, t-butyl, n-pentyl, heptyl, octyl, decyl, dodecyl, tridecyl, tetradecyl, pentadecyl or hexadecyl and can be unsubstituted or substituted with one or more substituents independently selected from the group consisting halogen, hydroxy, caboxy, oxo, nitro, haloalkyl, alkyl, alkenyl, alkynyl, alkaryl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkoxy, aryloxy, alkylamino, dialkylamino, alkoxycarbonyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano and ureido;

R 5 , R 7 and R 8 are independently selected from the group consisting of: hydrogen, alkyl, halogen, nitro, cyano, hydroxyl, amino, mercapto, formyl, carboxy, alkanoyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which can be substituted or unsubstituted;

R 6 is hydrogen, alkyl, halogen, nitro, cyano, hydroxyl, amino, mercapto, formyl, carboxy, alkanoyl, carbamoyl, unsubstituted alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; and tautomers or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is of Formula (II):

3. The compound of claim 1 , wherein Y is selected from the group consisting of:

4. The compound of claim 3 , wherein Y is selected from the group consisting of:

5. The compound of claim 1 , wherein R 6 is H or unsubstituted alkoxy or R 7 is H or a substituted or unsubstituted alkoxy.

6. The compound of claim 1 , wherein R 6 is H or —OR 9 , where R 9 is unsubstituted alkyl; substituted or unsubstituted cycloalkyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl.

7. The compound of claim 1 , wherein R 6 is H or —OR 9 , where R 9 is unsubstituted C 1 -C 6 alkyl.

8. The compound of claim 1 , wherein R 6 is H or —OR 9 , where R 9 is methyl, ethyl, propyl, isopropyl, 1-mthylpropy, 2-methylpropyl, butyl, t-butyl, pentyl or hexyl.

9. The compound of claim 1 , wherein R 7 is H or —OR 10 , where R 10 is substituted or unsubstituted alkyl; substituted or unsubstituted cycloalkyl; substituted or unsubstituted hetrocyclyl; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl.

10. The compound of claim 1 , wherein R 7 is H or —OR 10 , where R 10 is substituted or unsubstituted C 1 -C 6 alkyl.

11. The compound of claim 1 , wherein R 7 is H or —OR 10 , where R 10 is methyl, ethyl, propyl, isopropyl, 1-methylpropy, 2-methylpropyl, butyl, t-butyl, pentyl or hexyl.

12. The compound of claim 1 , wherein R 6 and R 7 are H or —OCH 3 .

13. The compound of claim 1 , wherein R 5 or R 8 are each independently hydrogen, alkyl, halogen, nitro, cyano, hydroxyl, alkoxy, carboxy, amino, alkylamino or dialkylamino.

14. The compound of claim 1 , wherein R 5 and R 8 are hydrogen, and R 6 and R 7 are H or —OCH 3 .

15. The compound of claim 1 , wherein the compound is of Formula (IV):

16. A compound selected from the group consisting of:

17. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

18. A method of treating cancer, the method comprising administering a therapeutically effective dose of a compound of claim 1 to a subject in need of treatment for cancer, and wherein the cancer is melanoma.

19. The method of claim 18 , wherein the method further comprises a first step of measuring the level of activity or expression of a cancer marker in one or more cell types relative to a reference level and the administering step is performed if the level is increased.

20. The method of claim 19 , wherein the subject is determined to have an increased level of activity or expression of an oncogene in one or more cell types relative to a reference level occurring in a cell selected from the group consisting of: a squamous cell; basal cell; and melanocyte.

21. The method of claim 20 , wherein the oncogene is selected from the group consisting of:

NRAS; BRAF; KIT; MAPK1/2; ERBB4; GRIN2A; GRM3; RAC1; PREX2; IDH1; PPP6C; and CDK4.

22. A method of treating melanoma comprising:

isolating one or more cells selected from the group consisting of a squamous cell, basal cell and melanocyte from a subject in need thereof;

measuring the expression of one or more cancer genes, oncogenes or tumor suppressor genes products in the one or more cells;

administering a therapeutically effective dose of an inhibitor of an immune checkpoint polypeptide to the subject if the expression of one or more cancer genes, oncogenes or tumor suppressor gene is not altered or decreased in the one or more cells as compared to a reference level; or

administering a therapeutically effective dose of a compound of claim 1 to the subject if the expression of one or more cancer genes, oncogenes or tumor suppressor gene products is elevated in the one or more cells as compared to a reference level.

23. The method of claim 22 , wherein the marker gene is selected from the group consisting of:

NRAS; BRAF; KIT; MAPK1/2; ERBB4; GRIN2A; GRM3; RAC1; PREX2; IDH1; PPP6C; and CDK4.

24. The method of claim 22 , wherein the immune checkpoint polypeptide is selected from: CTLA4A; CTLA4; Ki-67; CD-28; PD-1; TIM-3; and LAG-3.